Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab)) (CAT#: TAB-206)

Recombinant monoclonal antibody to CTLA4. Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human IgG2 monoclonal antibody, undergoing human trials for the treatment of cancer.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Binding profiles of ipilimumab-scFv/CTLA-4 and tremelimumab-scFv/CTLA-4 measured by SPR.

Figure 1 Binding profiles of ipilimumab-scFv/CTLA-4 and tremelimumab-scFv/CTLA-4 measured by SPR.

CTLA-4 was immobilized on the chip while serially diluted (A) ipilimumab-scFv or (B) tremelimumab-scFv with concentrations ranging from 6.25 nM to 200 nM were then flowed through the chip and the response units were measured.

He, M., Chai, Y., Qi, J., Zhang, C. W., Tong, Z., Shi, Y., ... & Gao, G. F. (2017). Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget, 8(40), 67129.

Figure 2 Modulation of CTLA4 and phosphoprotein expression in monocytes exposed ex vivo to tremelimumab.

Figure 2 Modulation of CTLA4 and phosphoprotein expression in monocytes exposed ex vivo to tremelimumab.

Monocytes were cultured in increasing concentrations of tremelimumab for 48 hours, after which were analyzed for intracellular flow cytometry. Data is presented as fold change from the baseline mean fluorescence intensity (MFI) at increasing concentrations of tremelimumab (0, 0.1, 1. 10. 15 and 100 mg/ml) presented in a semilogarithmic plot. Red triangles represent monocytes samples obtained from three patients with metastatic melanoma (MD: melanoma donors); black circles are results from monocytes analyzed from five healthy subjects (HD: healthy donors). a) Intracellular CTLA4 expression; b) pp38(pT180/pY182); c) pErk1/2 (T202/204); d) pAkt (pT308); e) pSTAT1(pY701); f) pSTAT3 (pY705); g) pSTAT5 (Y694); h) pSTAT6 (Y641). **p<0.01; ***p<0.001.

Comin-Anduix, B., Sazegar, H., Chodon, T., Matsunaga, D., Jalil, J., von Euw, E., ... & Koya, R. C. (2010). Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PloS one, 5(9), e12711.

Figure 3 Immune response against HCV antigens after tremelimumab.

Figure 3 Immune response against HCV antigens after tremelimumab.

(A) IFN-c producing T lymphocytes against HCV antigens were evaluated by ELISPOT assays at different time points after treatment. Antigens used were recombinant core, NS3, NS4, and NS5 proteins, and peptide pools spanning the whole HCV polyprotein. Results represent mean + SEM of spot forming cells (SFC). For peptides, values correspond to the sum of the different pools encompassed in each protein. (p <0.05 compared to day 0). (B) Representative example of anti-HCV responses obtained in patients B and F.

Sangro, B., Gomez-Martin, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., ... & Lasarte, J. J. (2013). A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. Journal of Hepatology, 59(1), 81-88.

Figure 4 Effect of tremelimumab on the suppressive activity of Tregs in vitro.

Figure 4 Effect of tremelimumab on the suppressive activity of Tregs in vitro.

CD4+ T cells were positively selected from PBMC samples using CD4 microbeads. CD4+ T cells were labeled with antibodies and used to sort CD4+ CD25+ CD127− Tregs and CD4+ CD25− CD127+ Teff by FACSAria. Tregs and Teff were cultured in triplicate wells alone or together at the ratios indicated with HLA-DR+ cells as APCs and anti-CD3/28 antibodies in the absence or presence of 15 μg/ml tremelimumab. Proliferation was measured by tritiated thymidine and reported as CPM (A). The percent suppression of Teff proliferation by Tregs was also determined (B). Data shown are derived from one donor and representative experiments from 3 different donors.

Khan, S., Burt, D. J., Ralph, C., Thistlethwaite, F. C., Hawkins, R. E., & Elkord, E. (2011). Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clinical Immunology, 138(1), 85-96.

Figure 5 Representative immunohistochemistry of inspiratory muscles at autopsy, 66 days after tremelimumab-durvalumab treatment.

Figure 5 Representative immunohistochemistry of inspiratory muscles at autopsy, 66 days after tremelimumab-durvalumab treatment.

Hematoxylin and eosin (H&E) sections show inflammatory myopathy in the diaphragm and intercostal muscles without rimmed vacuoles and without perifascicular atrophy, consistent with polymyositis. A mononuclear infiltrate is present which invades otherwise normal myofibers and completely effaces the background muscle fiber architecture in some areas. ATPase shows intense staining in small fibers compared to surrounding lighter, normal sized fibers in preserved areas of muscle, indicative of type II fiber atrophy. Trichrome shows mildly increased connective tissue, but shows no rimmed vacuoles, rods, or other inclusions. T cell co-receptor staining (CD3, CD4, CD8) revealed a mixed T-cell infiltrate which often completely effaced the myofascicular architecture. CD68 highlights necrotic myofibers scattered within the larger inflammatory infiltrate. PD-L1 expression was observed in blood vessels of dying muscle. Weak CTLA-4 expression was detected in necrotic myofibers. All images are 100× magnification.

John, S., Antonia, S. J., Rose, T. A., Seifert, R. P., Centeno, B. A., Wagner, A. S., & Creelan, B. C. (2017). Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab-durvalumab treatment. Journal for immunotherapy of cancer, 5(1), 54.


Specifications

  • Immunogen
  • Human CTLA-4.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG2
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • WB, IF, IP, Neut, FuncS, ELISA, FC
  • CAS
  • 745013-59-6
  • Generic Name
  • Ticilimumab (= tremelimumab)
  • UNII
  • QEN1X95CIX
  • MW
  • 146.380472 kDa

Product Property

  • Purity
  • >95%, by SDS-PAGE with silver staining, under reducing conditions.
  • Storage
  • Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.

Applications

  • Application Notes
  • The CTLA4 antibody has been reported in applications of SPR, FC, ELISPOT, Activ, IHC.

Target

  • Alternative Names
  • Ticilimumab (= tremelimumab);745013-59-6;ticilimumab;CP-675;206;Ticilimumab;CP-675;206;CTLA4;cytotoxic T-lymphocyte-associated protein 4;celiac disease 3 , CELIAC3;cytotoxic T-lymphocyte protein 4;CD;CD28;CD152;GSE;ICOS;CD152 isoform;celiac disease 3;cyto

Related Resources

  • Related Diseases

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Ticilimumab (= Tremelimumab)"

Afuco™ Anti-CTLA4 ADCC Recombinant Antibody (Ticilimumab (= Tremelimumab)), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CTLA4. Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human IgG2 monoclonal antibody, undergoing human trials for the treatment of cancer.

See other products for "CTLA4"

Human Antibody

CAT Product Name Application Type
TAB-067 Anti-Human CTLA4 Recombinant Antibody (Ipilimumab) WB, FuncS, IF, Neut, ELISA, FC, IP IgG1 - kappa

Immunotoxin

CAT Product Name Application Type
AGTO-G015E Anti-CTLA4 immunotoxin (scFv)-PE Cytotoxicity assay, Function study
AGTO-G015S Anti-CTLA4 immunotoxin (scFv)-Sap Cytotoxicity assay, Function study
AGTO-G015M Anti-CTLA4 immunotoxin (scFv)-Mel Cytotoxicity assay, Function study

Rat Antibody

CAT Product Name Application Type
TAB-195CL Mouse Anti-CTLA4 Recombinant Antibody (TAB-195CL) ELISA Mouse IgG

Chimeric Antibody

CAT Product Name Application Type
TAB-085MZ Anti-Human CTLA4 Recombinant Antibody (TGN2122.C) ELISA, FC Chimeric antibody (mouse/human)
TAB-086MZ Anti-Human CTLA4 Recombinant Antibody (TGN2422.C) ELISA, FC Chimeric antibody (mouse/human)
TAB-085MZ-S(P) Anti-Human CTLA4 Recombinant Antibody scFv Fragment (TGN2122.C) ELISA, FC Chimeric antibody (mouse/human)
TAB-086MZ-S(P) Anti-Human CTLA4 Recombinant Antibody scFv Fragment (TGN2422.C) ELISA, FC Chimeric antibody (mouse/human)
TAB-085MZ-F(E) Anti-Human CTLA4 Recombinant Antibody Fab Fragment (TGN2122.C) ELISA, FC Chimeric antibody (mouse/human)

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-0855 Hi-Affi™ Rabbit Anti-CTLA4 Recombinant Antibody (clone DS855AB) WB Rabbit IgG

Recombinant Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-067 Afuco™ Anti-CTLA4 ADCC Recombinant Antibody (Ipilimumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC ADCC enhanced antibody
AFC-TAB-206 Afuco™ Anti-CTLA4 ADCC Recombinant Antibody (Ticilimumab (= Tremelimumab)), ADCC Enhanced IF, IP, Neut, FuncS, ELISA ADCC enhanced antibody

Submit a review or a question
There are currently no Customer reviews or questions for TAB-206. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare